Clinical Trials Sponsored by Otic Pharma

Total 8339 results

LEO Pharma

Completed

Efficacy and Safety of Calcipotriol Plus Hydrocortisone Ointment Compared With Tacalcitol Ointment in Patients With Psoriasis on the Face and Skin Folds

Psoriasis Vulgaris

United Kingdom, France, Canada
LEO Pharma

Completed

A Plaque Test Comparing the Anti-psoriatic Effect of Marketed Products for Topical Use for Psoriasis Vulgaris

Psoriasis Vulgaris

France
LEO Pharma

Completed

Efficacy and Safety of Xamiol® Gel Compared to Calcipotriol Scalp Solution in Patients With Scalp Psoriasis

Scalp Psoriasis

China
LEO Pharma

Completed

Safety and Efficacy of LEO 80185 Gel in Adolescent Subjects (Aged 12 to 17) With Scalp Psoriasis

Scalp Psoriasis

Canada, United Kingdom, France
LEO Pharma

Completed

Safety and Efficacy of TACLONEX Ointment in Adolescent Patients (Aged 12 to 17 Years) With Psoriasis Vulgaris

Psoriasis Vulgaris

United States
LEO Pharma

Completed

Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel for up to a Year in Scalp Psoriasis

Psoriasis of Scalp

Canada, Denmark, France, Germany, United Kingdom
LEO Pharma

Completed

Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel in Scalp Psoriasis

Psoriasis of Scalp

Canada, Belgium, Finland, France, Germany, Netherlands, United Kingdom
UCB Pharma

Completed

Levetiracetam Versus Standard Antiepileptic Drugs (Carbamazepine and Valproate) Used as Monotherapy in Patients With Newly Diagnosed Epilepsy

Epilepsy

Australia, France, Germany, Italy, Poland, United Kingdom, Belgium, Spain, Switzerland, Austria, Bulgaria, Romania, Turkey, Denmark, Greece, Russian Federation, Netherlands, Hungary, Ireland, Slovakia, Sweden, Norway, Finland, Czech Republic
UCB Pharma

Terminated

Prevention of Asthma With Levocetirizine (36 Month Treatment) in Young Children Suffering From Eczema (Atopic Dermatitis) and Sensitized to Grass Pollen and House Dust Mite and Having Completed the Previous EPAAC Trial (NCT00152464)

Asthma

Italy, Poland, United Kingdom, Germany, Spain, Belgium, South Africa, Czech Republic, Australia, France
UCB Pharma

Completed

A 19-week Cognition Study of Levetiracetam in Children With Partial Onset Seizures

Epilepsy, Partial

United States, South Africa, Canada
LEO Pharma

Completed

Safety, Tolerability and Pharmacokinetics in AD Subjects and Healthy Subjects of Cutaneous Application of LEO 39652 Cream

Atopic Dermatitis

United Kingdom
UCB Pharma

Completed

Cardiac Effects of Rotigotine Transdermal System in Subjects With Advanced-stage Idiopathic Parkinson's Disease

Parkinson's Disease

South Africa
UCB Pharma

Completed

Post-Authorization Safety Study to Assess the Safety of Vimpat as add-on Therapy in Patients With Partial-onset Seizures (PASS)

Epilepsies, Partial

France, Germany, United Kingdom, Spain, Netherlands
UCB Pharma

Completed

Prostaglandin E1 in Outpatients With Intermittent Claudication

Stage II Peripheral Arterial Occlusive Disease | Intermittent Claudication Fontaine Stage II PAOD

Germany
UCB Pharma

Completed

Efficacy, Safety and Tolerability of Rotigotine Nasal Spray for the Acute Treatment of Parkinson Symptoms

Parkinson's Disease
UCB Pharma

Completed

A Trial of Neupro® (Rotigotine Transdermal Patch) in Patients With Parkinson's Disease Undergoing Surgery (NEUPOS)

Parkinson's Disease

Germany
UCB Pharma

Completed

Safety and Tolerability Trial of Switching From Ropinirole to Rotigotine

Parkinson's Disease
UCB Pharma

Completed

Efficacy, Safety and Tolerability of Rotigotine Nasal Spray for the Acute Treatment of RLS Symptoms

Restless Legs Syndrome

Germany
UCB Pharma

Completed

An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Advanced-Stage Parkinson's Disease

Advanced Stage Parkinson's Disease

France, Italy, Poland, United Kingdom, Spain, Germany, South Africa, New Zealand, Czech Republic, Hungary, Australia, Austria, Israel, Sweden, Norway, Croatia, Finland
UCB Pharma

Completed

A Trial to Evaluate the Effects of Rotigotine Transdermal Patch on Early Morning Motor Impairment and Sleep Disorders Idiopathic Parkinson's Disease

IDIOPATHIC PARKINSON'S DISEASE

Germany
UCB Pharma

Completed

Phase 3 Open-label Extension Trial With Rotigotine in Idiopathic Restless Legs Syndrome Subjects

Idiopathic Restless Legs Syndrome

Germany
UCB Pharma

Completed

Rotigotine Restless Legs Syndrome Dose Finding Trial

Idiopathic Restless Leg Syndrome

Germany
UCB Pharma

Completed

Trial to Assess the Efficacy and Safety of SPM 927 (200, 400, and 600mg/Day) in Subjects With Painful Distal Diabetic Neuropathy

Diabetic Neuropathies

United States
UCB Pharma

Completed

Safety and Tolerability of Intravenous SPM 927 as Replacement for Oral SPM 927 in Subjects With Partial Seizures

Epilepsies, Partial

United States
UCB Pharma

Completed

Long Term Follow-up Study With Keppra XR (Levetiracetam XR) for Partial Seizures

Epilepsy

United States, Poland, Mexico, Russian Federation
UCB Pharma

Completed

Open Study to Evaluate the Safety of Levocetirizine in Young Children (2 - 6 Years) Suffering From Allergic Rhinitis

Allergic Rhinitis
Innate Pharma

Completed

Study on the Anti-tumor Activity, Safety and Pharmacology of IPH2101 in Patients With Smoldering Multiple Myeloma (KIRMONO)

Smoldering Multiple Myeloma

United States
Innate Pharma

Completed

A Safety and Tolerability Extension Trial Assessing Repeated Dosing of Anti-KIR (1-7F9) Human Monoclonal Antibody in Patients With Acute Myeloid Leukaemia

Acute Myeloid Leukemia

France
Innate Pharma

Completed

Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101 Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse (KIRIMID)

Patients With Multiple Myeloma Experiencing a | First or Second Relapse

United States
UCB Pharma

Completed

Wheal and Flare Reaction During 24 Hours in Allergic Volunteers.

Allergy

France
UCB Pharma

Completed

Evaluation of Treatment Satisfaction in Children With an Allergy and Who Received an Antihistamine

Allergies

United States
UCB Pharma

Completed

Evaluation of Efficacy and Safety of Levocetirizine to Subjects With Perennial Allergic Rhinitis to House Dust Mites

Rhinitis | Allergic | Perennial
UCB Pharma

Completed

Efficacy of Levocetirizine and Cetirizine in Reducing Symptoms of Seasonal Allergic Rhinitis in Ragweed Sensitive Subjects

Rhinitis, Allergic, Seasonal
UCB Pharma

Completed

Efficacy and Safety of Levocetirizine and Fexofenadine in Reducing Symptoms of Seasonal Allergic Rhinitis

Rhinitis, Allergic, Seasonal
UCB Pharma

Completed

Safety and Tolerability of Levetiracetam Intravenous 15 Minute Infusion in Subjects Suffering From Partial Onset Seizures

Epilepsy
UCB Pharma

Completed

Levetiracetam in the Treatment of Neuroleptic-induced Tardive Dyskinesia

Dyskinesia, Medication-induced

Belgium, Bulgaria
UCB Pharma

Completed

Levetiracetam Treatment in Adult Subjects With Parkinson's Disease Experiencing Troublesome Dyskinesias

Idiopathic Parkinson Disease
UCB Pharma

Completed

Study on Safety and Efficacy of Levetiracetam in the Adjunctive Treatment of Female Subjects With C1 Catamenial Epilepsy

Epilepsy
UCB Pharma

Completed

Study to Assess the Efficacy and Safety of Levetiracetam for the Treatment of Social Anxiety Disorder (Generalized Type)

Anxiety Disorders
LEO Pharma

Completed

A Psoriasis Plaque Test Comparing Products for the Treatment of Psoriasis Vulgaris

Psoriasis Vulgaris

France
LEO Pharma

Completed

An Exploratory Psoriasis Plaque Test Study With LEO 29102 Plus Calcipotriol, Ointment, in Psoriasis Vulgaris

Psoriasis Vulgaris

France
UCB Pharma

Completed

A Study to Test the Effect of CDP870 in the Treatment of Crohn's Disease Over 26 Weeks, Comparing CDP870 to a Dummy Drug (Placebo)

Crohn's Disease
UCB Pharma

Completed

Bio-availability Comparison of Three Formulations of Certolizumab Pegol in Healthy Volunteers

Bioavailability Study on Healthy Volunteers

France
UCB Pharma

Completed

Study to Test the Effect of CDP870 in the Treatment of Crohn's Disease Over 26 Weeks, Comparing CDP870 to a Dummy Drug (Placebo), Following 3 Doses of Active Drug (CDP870).

Crohn's Disease
UCB Pharma

Completed

A Single Center, Randomized, Double-blind, Crossover Pilot Trial Comparing the Onset of Action of Parcopa™ With Sinemet® in Subjects With Stable Parkinson's Disease

Parkinson's Disease

United States
UCB Pharma

Completed

Efficacy and Safety of CDP870 Versus Placebo in the Treatment of the Signs and Symptoms of Rheumatoid Arthritis

Rheumatoid Arthritis
UCB Pharma

Completed

A Multicenter, Open-label Randomized Crossover Trial to Assess Subject Preference for Kemstro™ Compared to Conventional Baclofen Tablets in Subjects With Stable Multiple Sclerosis

Multiple Sclerosis

United States
UCB Pharma

Completed

A Multicenter, Open-Label, Randomized Crossover Trial to Assess Subject Preference for Alprazolam Orally Disintegrating Tablets Compared to Conventional Alprazolam Tablets in Subjects With Anxiety

ANXIETY

United States
HRA Pharma

Completed

Safety, Tolerability, and Efficacy of ellaOne® (Ulipristal Acetate) for Emergency Contraception in Postmenarcheal Adolescent Girls and Women

Contraception

United States, Sweden, United Kingdom
LEO Pharma

Completed

Preventive Treatment of VETD in Patients With Multiple Myeloma Receiving Chemotherapy With Thalidomide or Lenalinomide.

Multiple Myeloma

3

Subscribe